Ser286

Site Information
TVLPNNLsPFAMDKK SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 10795897

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:	brain cancer ( 3 , 4 ) , neuroendocrine cancer ( 3 , 4 )
Relevant cell line - cell type - tissue:	3T3 (fibroblast) [CDC42 (human), transfection] ( 2 ) , 3T3 (fibroblast) [KRas (human), transfection] ( 2 ) , 3T3 (fibroblast) ( 2 ) , BaF3 ('B lymphocyte, precursor') [JAK3 (human), transfection] ( 1 ) , brain ( 3 , 4 )

Upstream Regulation
Regulatory protein:	PAK4 (mouse) ( 2 )

References
1	Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia 32 28852199 Curated Info
2	Gnad F, et al. (2013) Systems-wide Analysis of K-Ras, Cdc42, and PAK4 Signaling by Quantitative Phosphoproteomics. Mol Cell Proteomics 12, 2070-80 23608596 Curated Info
3	Guo A (2011) CST Curation Set: 12733; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981 Curated Info
4	Guo A (2011) CST Curation Set: 12734; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981 Curated Info